The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology

Luke T. Condon, Nicholas D. Stafford, Karen J. Bedford, Alistair W. MacDonald, Stephen Atkin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Conventional chemotherapy has no role to play in the curative treatment of laryngeal carcinoma, yet the mortality rate from advanced disease has improved little over the last 20 years. Somatostatin is a naturally occurring peptide, which exerts anti-proliferative and anti-angiogenic effects via 5 membrane-bound receptor subtypes (SSTRs 1-5). We have previously studied the expression of SSTRs 1 and 2 and demonstrated loss of SSTR2 in laryngeal carcinoma. This study was therefore undertaken to study the expression of the remaining SSTR subtypes in laryngeal pathology. The expression of SSTRs 3, 4 and 5 was studied in benign (Reinke's oedema), pre-malignant and malignant laryngeal specimens using immunohistochemistry. There was very little expression of SSTR3, with low to moderate levels detected in just 1/6 (17%) benign and pre-malignant specimens and 3/12 (25%) malignant laryngeal tumours. A variable degree of SSTR4 expression was detected across the three groups, with low to moderate levels in 3/6 (50%) benign specimens, compared to only 1/6 (17%) pre-malignant specimens but 8/12 (67%) malignant laryngeal tumours. The majority of all specimens, however, demonstrated moderate to high levels of expression of SSTR5. This receptor was detected in 4/6 (67%) benign, all pre-malignant (100%) and 10/12 (83%) malignant cases. All the laryngeal carcinomas studied expressed either SSTR4 or SSTR5, with 60% expressing both, but very few expressing SSTR3. Somatostatin receptors warrant further investigation to determine whether they have a therapeutic role in carcinoma of the larynx.

Original languageEnglish
JournalEuropean Archives of Oto-Rhino-Laryngology
Volume265
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jul 2008
Externally publishedYes

Fingerprint

Pathology
Carcinoma
Somatostatin Receptors
Larynx
Somatostatin
Edema
Neoplasms
Immunohistochemistry
Drug Therapy
Peptides
Membranes
Mortality
somatostatin receptor subtype-4
somatostatin receptor 5
somatostatin receptor 3
Therapeutics
somatostatin receptor type 1
somatostatin receptor 2

Keywords

  • Immunohistochemistry
  • Larynx
  • Reinke's oedema
  • Somatostatin receptors
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology. / Condon, Luke T.; Stafford, Nicholas D.; Bedford, Karen J.; MacDonald, Alistair W.; Atkin, Stephen.

In: European Archives of Oto-Rhino-Laryngology, Vol. 265, No. SUPPL. 1, 07.2008.

Research output: Contribution to journalArticle

Condon, Luke T. ; Stafford, Nicholas D. ; Bedford, Karen J. ; MacDonald, Alistair W. ; Atkin, Stephen. / The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology. In: European Archives of Oto-Rhino-Laryngology. 2008 ; Vol. 265, No. SUPPL. 1.
@article{c73dda72115744bc8119516ade4c577e,
title = "The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology",
abstract = "Conventional chemotherapy has no role to play in the curative treatment of laryngeal carcinoma, yet the mortality rate from advanced disease has improved little over the last 20 years. Somatostatin is a naturally occurring peptide, which exerts anti-proliferative and anti-angiogenic effects via 5 membrane-bound receptor subtypes (SSTRs 1-5). We have previously studied the expression of SSTRs 1 and 2 and demonstrated loss of SSTR2 in laryngeal carcinoma. This study was therefore undertaken to study the expression of the remaining SSTR subtypes in laryngeal pathology. The expression of SSTRs 3, 4 and 5 was studied in benign (Reinke's oedema), pre-malignant and malignant laryngeal specimens using immunohistochemistry. There was very little expression of SSTR3, with low to moderate levels detected in just 1/6 (17{\%}) benign and pre-malignant specimens and 3/12 (25{\%}) malignant laryngeal tumours. A variable degree of SSTR4 expression was detected across the three groups, with low to moderate levels in 3/6 (50{\%}) benign specimens, compared to only 1/6 (17{\%}) pre-malignant specimens but 8/12 (67{\%}) malignant laryngeal tumours. The majority of all specimens, however, demonstrated moderate to high levels of expression of SSTR5. This receptor was detected in 4/6 (67{\%}) benign, all pre-malignant (100{\%}) and 10/12 (83{\%}) malignant cases. All the laryngeal carcinomas studied expressed either SSTR4 or SSTR5, with 60{\%} expressing both, but very few expressing SSTR3. Somatostatin receptors warrant further investigation to determine whether they have a therapeutic role in carcinoma of the larynx.",
keywords = "Immunohistochemistry, Larynx, Reinke's oedema, Somatostatin receptors, Squamous cell carcinoma",
author = "Condon, {Luke T.} and Stafford, {Nicholas D.} and Bedford, {Karen J.} and MacDonald, {Alistair W.} and Stephen Atkin",
year = "2008",
month = "7",
doi = "10.1007/s00405-007-0539-y",
language = "English",
volume = "265",
journal = "Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde",
issn = "0003-9195",
publisher = "Springer Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology

AU - Condon, Luke T.

AU - Stafford, Nicholas D.

AU - Bedford, Karen J.

AU - MacDonald, Alistair W.

AU - Atkin, Stephen

PY - 2008/7

Y1 - 2008/7

N2 - Conventional chemotherapy has no role to play in the curative treatment of laryngeal carcinoma, yet the mortality rate from advanced disease has improved little over the last 20 years. Somatostatin is a naturally occurring peptide, which exerts anti-proliferative and anti-angiogenic effects via 5 membrane-bound receptor subtypes (SSTRs 1-5). We have previously studied the expression of SSTRs 1 and 2 and demonstrated loss of SSTR2 in laryngeal carcinoma. This study was therefore undertaken to study the expression of the remaining SSTR subtypes in laryngeal pathology. The expression of SSTRs 3, 4 and 5 was studied in benign (Reinke's oedema), pre-malignant and malignant laryngeal specimens using immunohistochemistry. There was very little expression of SSTR3, with low to moderate levels detected in just 1/6 (17%) benign and pre-malignant specimens and 3/12 (25%) malignant laryngeal tumours. A variable degree of SSTR4 expression was detected across the three groups, with low to moderate levels in 3/6 (50%) benign specimens, compared to only 1/6 (17%) pre-malignant specimens but 8/12 (67%) malignant laryngeal tumours. The majority of all specimens, however, demonstrated moderate to high levels of expression of SSTR5. This receptor was detected in 4/6 (67%) benign, all pre-malignant (100%) and 10/12 (83%) malignant cases. All the laryngeal carcinomas studied expressed either SSTR4 or SSTR5, with 60% expressing both, but very few expressing SSTR3. Somatostatin receptors warrant further investigation to determine whether they have a therapeutic role in carcinoma of the larynx.

AB - Conventional chemotherapy has no role to play in the curative treatment of laryngeal carcinoma, yet the mortality rate from advanced disease has improved little over the last 20 years. Somatostatin is a naturally occurring peptide, which exerts anti-proliferative and anti-angiogenic effects via 5 membrane-bound receptor subtypes (SSTRs 1-5). We have previously studied the expression of SSTRs 1 and 2 and demonstrated loss of SSTR2 in laryngeal carcinoma. This study was therefore undertaken to study the expression of the remaining SSTR subtypes in laryngeal pathology. The expression of SSTRs 3, 4 and 5 was studied in benign (Reinke's oedema), pre-malignant and malignant laryngeal specimens using immunohistochemistry. There was very little expression of SSTR3, with low to moderate levels detected in just 1/6 (17%) benign and pre-malignant specimens and 3/12 (25%) malignant laryngeal tumours. A variable degree of SSTR4 expression was detected across the three groups, with low to moderate levels in 3/6 (50%) benign specimens, compared to only 1/6 (17%) pre-malignant specimens but 8/12 (67%) malignant laryngeal tumours. The majority of all specimens, however, demonstrated moderate to high levels of expression of SSTR5. This receptor was detected in 4/6 (67%) benign, all pre-malignant (100%) and 10/12 (83%) malignant cases. All the laryngeal carcinomas studied expressed either SSTR4 or SSTR5, with 60% expressing both, but very few expressing SSTR3. Somatostatin receptors warrant further investigation to determine whether they have a therapeutic role in carcinoma of the larynx.

KW - Immunohistochemistry

KW - Larynx

KW - Reinke's oedema

KW - Somatostatin receptors

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=47349129231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47349129231&partnerID=8YFLogxK

U2 - 10.1007/s00405-007-0539-y

DO - 10.1007/s00405-007-0539-y

M3 - Article

C2 - 18066572

AN - SCOPUS:47349129231

VL - 265

JO - Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde

JF - Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde

SN - 0003-9195

IS - SUPPL. 1

ER -